Keywords: ADT; Radical prostatectomy; Radiation therapy; Systemic therapy; Toxicity;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: A.F; Alexander Falk; ADT; Androgen Deprivation Therapy; AMSTAR; Assessing the Methodological Quality of Systematic Reviews; BED; Biological Effective Dose; b-PFS; Biochemical Progression-Free Survival; BT; Brachytherapy; CI; Confidence Interval; CONSORT;
Keywords: Prostate cancer recurrence; Androgen deprivation therapy (ADT); Choline-PET/CT; PSMA-PET/CT; Robotic salvage lymph node dissection; Complete biochemical response (cBCR); ADT; androgen deprivation therapy; BCR; biochemical recurrence; cBCR; complete bioche
Keywords: androgen antagonists; dementia; prostatic neoplasms; Alzheimer disease; cognition; ADT; androgen deprivation therapy; ICCTF; International Cognition and Cancer Task Force;
Keywords: Insulin; C-peptide; IGF-1; Body composition; 1-RM; 1 Repetition Maximum; ADT; Androgen Deprivation Therapy; AUC; Area Under the Curve; BMI; Body Mass Index; CRP; C-reactive Protein; CVD; Cardiovascular Disease; DBP; Diastolic Blood Pressure; FFM; Fat Free
Keywords: Prostate cancer; Cause-Specific Mortality; Survival analysis; Cancer registry; Treatment; ADT;
Keywords: atrial fibrillation; CLOSE protocol; contact force; contiguity; lesion depth; pulmonary vein isolation; ADT; antiarrhythmic drug therapy; AF; atrial fibrillation; AFL; atrial flutter; AI; ablation index; ALCI; ablation line contiguity index; AT; atrial ta
Keywords: DHEA; dehydroepiandrosterone; DHEA-S; DHEA-sulfate; 5-Diol; androstenediol; 4-Dione; androstenedione; DHT; dihydrotestosterone; ADT; androsterone; ADT-G; ADT-glucuronide; 3α-diol-3G; androstane-3α, 17β-diol 3-glucuronide; 3α-diol-17G; androstane-3α,
Keywords: Castrate-resistant prostate cancer; CRPC; Androgen deprivation therapy; ADT; LHRH; Immune therapy; Skeletal-related event (SRE);
Keywords: adt; air dry tonne of pulp contains exactly 9 kg of bone dry fibre and 1 kg of water (i.e. 10% moisture content); PPW; pulp and paper wastewater; AGS; aerobic granular sludge; Aerobic granulation; Biological treatment; Pulp and paper mill effluent; Wastew
Keywords: 6MWT; 6-Minute Walk Test; AACE; American Association of Clinical Endocrinologists; ACE; American College of Endocrinology; ADT; androgen deprivation therapy; BMI; body mass index; BRS; baroreflex sensitivity; CAC; coronary artery calcium; CAD; coronary ar
Keywords: prostatic neoplasms; prostate-specific antigen; brachytherapy; androgen antagonists; disease-free survival; ADT; androgen deprivation therapy; bDFS; biochemical disease-free survival; BF; biochemical failure; EBRT; external beam radiotherapy; LDR-BT; low
Keywords: AD; Anaerobic Digestion; ADT; Advanced Digestion Technology; BMP; Bio-Methane Potential; COD; Chemical Oxygen Demand; CSTR; Continually Stirred Tank Reactor; DM; Dry Matter; DSM; Dutch State Mine; EPS; Extracellular Polymeric Substance; FW; Food Waste; GE
Keywords: ADT; antidepressant treatment; ANCOVA; analysis of covariance; ATRQ; Massachusetts General Hospital Antidepressant Treatment Response Questionnaire; BMI; body mass index; CGI-I; Clinical Global Impressions - Improvement; DSM-IV-TR; Diagnostic and Statis
Keywords: Urolithins; Prostate cancer; Interactions; Ellagitannins gut metabolites; ADT; androgen deprivation therapy; AR; androgen receptor; bic; bicalutamide; CI; combination index; DHT; dihydrotestosterone; GnRH; gonadotropin-releasing hormone; PSA; prostate spe
Keywords: prostatic neoplasms; neoplasm recurrence; local; ultrasound; high-intensity focused; transrectal; postoperative complications; salvage therapy; ADT; androgen deprivation therapy; AE; adverse event; CaP; prostate cancer; EBRT; external beam radiation thera
Keywords: prostatic neoplasms; prostatectomy; high-intensity focused ultrasound ablation; cryotherapy; robotic surgical procedures; ADT; androgen deprivation therapy; BCR; biochemical recurrence; EBRT; external beam radiotherapy; HIFU; high intensity focused ultras
Keywords: prostatic neoplasms; castration-resistant; subcutaneous fat; prognosis; tomography; x-ray computed; mortality; ADT; androgen deprivation therapy; ARAT; androgen receptor axis targeted; BMI; body mass index; CCI; Charlson Comorbidity Index; CRPC; castratio
Keywords: prostatic neoplasms; androgen antagonists; non-alcoholic fatty liver disease; Medicare; SEER program; ADT; androgen deprivation therapy; AJCC; American Joint Committee on Cancer; NAFLD; nonalcoholic fatty liver disease; NASH; nonalcoholic steatohepatitis;
Keywords: ADT; androgen deprivation therapy; AE; adverse event; CRPC; castration-resistant prostate cancer; LHRH; luteinizing hormone-releasing hormone; mCRPC; metastatic CRPC; MFS; metastase-free survival; nmCRPC; non-metastatic CRPC; PFS; progression-free surviva
Keywords: prostatic neoplasms; castration-resistant; surveys and questionnaires; case reports; practice patterns; physicians; ADT; androgen deprivation therapy; CME; continuing medical education; CT; computerized tomography; LHRH; luteinizing hormone-releasing horm
Keywords: PC; prostate cancer; mPC; metastatic prostate cancer; ADT; androgen deprivation therapy; CRPC; castration resistant prostate cancer; mCRPC; metastatic CRPC; SNP; single nucleotide polymorphism; CNV; copy number variation; AR; androgen receptor; CTC; circu
Keywords: Temporal lobe epilepsy; Pharmaco-genetic; Parvalbumin neurons; Pyramidal neurons; ADD; Afterdischarge duration; ADT; Afterdischarge threshold; AEDs; Anti-epileptic drugs; ACSF; Artificial cerebrospinal fluid; CNO; Clozapine-N-oxide; DREADD; Designer Recep
Keywords: 4CL; 4-coumarate: CoA ligase; ADT; arogenate dehydratase; AIC; Akaike's Information Criteria; C4H; cinnamate 4-hyrdoxylase; CA; cinnamate; CCR; cinnamoyl-CoA reductase; FCC; flux control coefficient; HCT; hydroxycinnamoyl CoA: shikimate hydroxycinnamoyl t
Keywords: BMI; Body Mass Index; mTOR; Mechanistic target of Rapamycin; NOD; New onset diabetes; HbA1c; Hemoglobin A1c; ADT; Androgen Deprivation Therapy; GLP-1; Glucagon Like peptide; CVD; Cardiovascular disease; HIV; Human Immunodeficiency Virus; LDL; Low density
Keywords: ADT; androgen deprivation therapy; PSA; prostate specific antigen; DRE; digital rectal examination; Skin metastasis; Prostate cancer; Africa;
Keywords: prostatic neoplasms; radiotherapy; recurrence; salvage therapy; high-intensity focused ultrasound ablation; ADT; androgen deprivation therapy; BRFS; biochemical recurrence-free survival; CSS; cancer specific survival; EBRT; external beam radiotherapy; HIF
Keywords: ADD; afterdischarge duration; ADT; afterdischarge threshold; BLA; basolateral amygdala; DPAG; dorsal periaqueductal gray; DR; dorsal raphe nucleus; DRD; dorsal region of DR; DRVL; DR ventrolateral; EEG; electroencephalography; FST; forced swimming test; G
Keywords: ADT; Gene polymorphism; Oncologic outcome; Prostate cancer; Racial difference;
Keywords: ADT; Androgen deprivation therapy; AR; Androgen receptor; CRPC; Castration resistant prostate cancer; DHT; Dihydrotestosterone; EGF; Epidermal growth factor; EMT; Epithelial mesenchymal transition; ERβ; Estrogen receptor β; FGF; Fibroblast growth factor
Keywords: Sorafenib; Enzalutamide; Castration-resistant prostate cancer; Androgen receptor; Tyrosine kinase; PCa; prostate cancer; CRPC; castration-resistant prostate cancer; ADT; androgen deprivation therapy; AR; androgen receptor; Enz; enzalutamide; Sor; sorafeni
Keywords: Acrp30; Adipocyte complement related protein 30kda; AdipoR1; Adiponectin receptor1; AdipoR2; Adiponectin receptor2; AdipoQ; Adiponectin precursor; APN; Adiponectin; AMPK; Adenosine monophosphate activated protein kinase; ADT; Androgen deprivation therapy;
Keywords: LHRH; luteinizing hormone releasing hormone; ADT; androgen depletion therapy; CRPC; castration-resistant prostate cancer; CYP17; cytochrome P450 c17; MR; mineralocorticoid receptor; ER; estrogen receptor; PR; progestins receptor; GR; glucocorticoid recept
Keywords: Hydrogen sulphide; Stroke; Toxic effect; Neuroprotection; 3MST; 3-mercaptopyruvate sulfurtransferase; ADT; 5-(4-methoxyphenyl)-3H-1,2-dithiole-3-thione; AIF; apoptosis-inducing factor; Akt; protein kinase B; APAF-1; Apoptotic protease activating factor 1;
Keywords: ablation techniques; high-intensity focused ultrasound ablation; prostatic neoplasms; ADT; androgen deprivation therapy; AUR; acute urinary retention; BCR; biochemical recurrence; ED; erectile dysfunction; EORTC; European Organization for Research and Tre
Keywords: Iodine doped graphene; Catalyst; Fuel cell; ADT;
Keywords: AF substrate; atrial fibrillation; atrial remodeling; electrophysiology testing; ADT; activation dispersion time; AF; atrial fibrillation; CS; coronary sinus; ÎED; rate dependence of electrogram duration; ED; electrogram duration; ERP; effective refracto
In silico selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell
Keywords: ADT; androgen deprivation therapy; AR; androgen receptor; LBD; ligand binding domain; PCa; prostate cancer; SARM; selective androgen receptor modulator; VS; virtual screening; SBVS; structure-based virtual screening; WCRF; World Cancer Research Fund Inter
Keywords: prostatic neoplasms; immunotherapy; ADT; androgen deprivation therapy; APC; antigen presenting cell; CRPC; castration resistant prostate cancer; GM-CSF; granulocyte-macrophage colony-stimulating factor; mCRPC; metastatic castration resistant prostate canc
27-hydroxycholesterol: A novel player in molecular carcinogenesis of breast and prostate cancer
Keywords: 27-OHC; 27-hydroxycholesterol; ADT; androgen deprivation therapy; AR; androgen receptor; ATF4; Activating Transcription Factor 4; ATF6; Activating Transcription Factor 6; C/EBP; CCAAT / Enhancer binding proteins; CHOP; C/EBP homologous protein; CIP2A; can
Keywords: AD; afterdischarge; ADD; afterdischarge duration; ADHD; attention deficit hyperactivity disorder; ADT; afterdischarge threshold; AMPA; α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; ASD; autism spectrum disorder; B6; C57BL/6; BLA; basolateral amyg
Keywords: prostatic neoplasms; orchiectomy; testosterone; triptorelin pamoate; castration; male; ADT; androgen deprivation therapy; BMI; body mass index; CV; coefficient of variance; DHEAS; dehydroepiandrosterone sulfate; FSH; follicle-stimulating hormone; LC-MS/MS
Keywords: prostatic neoplasms; neoplasm staging; practice guidelines as topic; guideline adherence; ADT; androgen deprivation therapy; APC; advanced prostate cancer; CRPC; castration resistant prostate cancer; EMR; electronic medical record; IUOGP; integrated urolo
Keywords: AA; amino acid/amino acids; AAD; amino acid detection; ADI; arginine deiminase; ADT; arginine deprivation therapy; ALL; acute lymphoblastic leucemia; APCI; atmospheric pressure chemical ionization; APPI; atmospheric pressure photo ionization; AQC; aminoqu
Keywords: prostatic neoplasms; androgen antagonists; antineoplastic agents; hormonal; drug related side effects and adverse reactions; risk; ADT; androgen deprivation therapy; AMI; acute myocardial infarction; CADT; continuous ADT; GnRH; gonadotropin-releasing horm
Keywords: prostatic neoplasms; prostatectomy; lymph node excision; lymphatic metastasis; mortality; ADT; androgen deprivation therapy; CCI; Charlson comorbidity index; ECOG; Eastern Cooperative Oncology Group; LN; lymph node; NCDB; National Cancer Database; OS; ove
Keywords: prostatic neoplasms; neoplasm recurrence; local; androgen antagonists; salvage therapy; mortality; ADT; androgen deprivation therapy; AUA; American Urological Association; PSA; prostate specific antigen; SADT; salvage androgen deprivation therapy; TOAD;
Keywords: prostatic neoplasms; testosterone; prostate-specific antigen; leuprolide; mortality; ADT; androgen deprivation therapy; CAD; continuous androgen deprivation; CRPC; castration resistant prostate cancer; CSS; cause specific survival; IAD; intermittent andro
Keywords: prostatic neoplasms; prostatectomy; radiotherapy; toxicity; mortality; ADT; androgen deprivation therapy; EBRT; external beam radiation therapy; GI; gastrointestinal; HRQOL; health related quality of life; PCa; prostate cancer; RP; radical prostatectomy;
Keywords: prostatic neoplasms; radiotherapy; prostatectomy; erectile dysfunction; urinary incontinence; ADT; androgen deprivation therapy; aRT; adjuvant radiotherapy; CCI; Charlson comorbidity index; ED; erectile dysfunction; EF; erectile function; IIEF; Internati